JGUA
BSX icon

John G. Ullman & Associates’s Boston Scientific BSX Stock Holding History

John G. Ullman & Associates’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,874
Closed -$201K – 177
2025
Q2 		$201K Buy
+1,874
New +$190K 0.03% 169
2025
Q1 		– Sell
-2,391
Closed -$214K – 172
2024
Q4 		$214K Buy
+2,391
New +$210K 0.03% 166

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

John G. Ullman & Associates's BSX Position: Q3 2025 in Review

John G. Ullman & Associates sold out of Boston Scientific (BSX) in Q3 2025, closing a stake of 1,874 shares — an estimated $201K sold.

John G. Ullman & Associates first reported a position in BSX in Q4 2024 and held it in 2 quarters. The position peaked at $214K in Q4 2024. 1,708 funds tracked by Wall St. Rank hold BSX as of Q3 2025.

  • John G. Ullman & Associates reported no remaining Boston Scientific position as of Q3 2025 after selling out during the quarter.
  • John G. Ullman & Associates sold 1,874 Boston Scientific shares in Q3 2025, an estimated $201K.
  • John G. Ullman & Associates first reported a position in Boston Scientific in Q4 2024 and held it in 2 quarters.
  • John G. Ullman & Associates's Boston Scientific position peaked at $214K in Q4 2024.
  • 1,708 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2025.

Based on John G. Ullman & Associates's 13F filing for Q3 2025, filed 5 Nov 2025.